Review
doi: 10.1254/fpj.140.235.
[Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)]
[Article in
Japanese]
- PMID: 23138323
- DOI: 10.1254/fpj.140.235
Item in Clipboard
Review
[Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)]
[Article in
Japanese]
Nihon Yakurigaku Zasshi.
2012 Nov.
No abstract available
Similar articles
-
Azacitidine.Nat Rev Drug Discov. 2005 Apr;4(4):275-6. doi: 10.1038/nrd1698. Nat Rev Drug Discov. 2005. PMID: 15861567 No abstract available.
-
Azacitidine.Nat Rev Drug Discov. 2005 May;Suppl:S6-7. doi: 10.1038/nrd1726. Nat Rev Drug Discov. 2005. PMID: 15962522
-
Advances in myelodysplastic syndrome: nursing implications of azacitidine.Clin J Oncol Nurs. 2005 Aug;9(4):417-23. doi: 10.1188/05.CJON.417-423. Clin J Oncol Nurs. 2005. PMID: 16117208 Review.
-
Intravenous azacitidine for MDS.Clin Adv Hematol Oncol. 2007 Mar;5(3):234. Clin Adv Hematol Oncol. 2007. PMID: 17519884 No abstract available.
-
Azacitidine and the beginnings of therapeutic epigenetic modulation.Expert Opin Pharmacother. 2008 Aug;9(11):1981-6. doi: 10.1517/14656566.9.11.1981. Expert Opin Pharmacother. 2008. PMID: 18627335 Review.
Cited by
-
5-Aza-2''-deoxycytidine inhibits retinoblastoma cell by reactivating epigenetically silenced RASSF1A gene.Int J Ophthalmol. 2014 Feb 18;7(1):51-6. doi: 10.3980/j.issn.2222-3959.2014.01.09. eCollection 2014. Int J Ophthalmol. 2014. PMID: 24634863 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
